Last reviewed · How we verify
Aleor Dermaceuticals Limited — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Differin 0.3% Topical Gel | Differin 0.3% Topical Gel | phase 3 | Retinoid (third-generation) | Retinoic acid receptor gamma (RARγ) | Dermatology |
Therapeutic area mix
- Dermatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Apotex Inc. · 1 shared drug class
- Galderma R&D · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Aleor Dermaceuticals Limited:
- Aleor Dermaceuticals Limited pipeline updates — RSS
- Aleor Dermaceuticals Limited pipeline updates — Atom
- Aleor Dermaceuticals Limited pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Aleor Dermaceuticals Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aleor-dermaceuticals-limited. Accessed 2026-05-16.